Dr. Srivastava is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
Ann Arbor, MI 48109
Summary
- Dr. Arnav Srivastava is an urologic oncology fellow at the University of Michigan. He obtained his MD, MPH from The Johns Hopkins University School of Medicine in Baltimore, MD. He then completed his urology residency at Rutgers Robert Wood Johnson University Hospital in New Brunswick, NJ.
He has clinical interests in urologic malignancies including prostate, bladder, and kidney cancer.
He has research interests in health services research, health economics, insurance design, and biomarker development.
He has more than 50 publications and over 1000 citings.
Education & Training
University of Michigan Health SystemFellowship, Urologic Surgical Oncology, 2023 - 2026
Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Urology, 2018 - 2023
Johns Hopkins University School of MedicineClass of 2017
Certifications & Licensure
MI State Medical License 2023 - 2026
NJ State Medical License 2019 - 2025
Publications & Presentations
PubMed
- 5 citationsUpdates on enhanced recovery after surgery for radical cystectomy.Grace Lee, Hiren V Patel, Arnav Srivastava, Saum Ghodoussipour
Therapeutic Advances in Urology. 2022-07-12 - 7 citationsThe Urology Match Process and the Limited Value of Post-Interview Communication for Program Directors.Nicholas J. Farber, Christopher J. Neylan, Arnav Srivastava, Shashank S. Pandya, Amy Kaplan
Urology. 2019-06-01 - 87 citationsClinical Stage Migration and Survival for Renal Cell Carcinoma in the United States.Hiten D. Patel, Mohit Gupta, Gregory Joice, Arnav Srivastava, Ridwan Alam
European Urology Oncology. 2019-07-01
Press Mentions
Exploring Impact of Surgery Delays for Clinical Renal Cell Carcinoma Patients During the COVID-19 PandemicFebruary 11th, 2021
Study Supports Changing Classification of Renal Cell CarcinomaJuly 6th, 2020
Similar Incidence of DNA Damage Response Pathway Alterations Between Localized and Metastatic Prostate CancerMay 3rd, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
